Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Annals of Hematology|January 9, 2019
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?Dai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
Oncotarget|July 11, 2018
Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysisDai Chihara, Nathan H Fowler, Yasuhiro Oki, et al.
Leukemia & Lymphoma|April 15, 2016
Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphomaSarah A Milgrom, Chan Y Cheah, Chelsea C Pinnix, et al.
Cancer Medicine|November 18, 2021
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trialSriram Balasubramanian, Brendan Hodkinson, Stephen J Schuster, et al.
Leukemia & Lymphoma|June 26, 2019
Additional therapy improves outcomes in completely resected, limited-stage follicular lymphomaTherese Y Andraos, Zeina Ayoub, Loretta J Nastoupil, et al.
Leukemia & Lymphoma|April 4, 2019
Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapyZeina Ayoub, Therese Andraos, Sarah A Milgrom, et al.
Ophthalmic Plastic and Reconstructive Surgery|September 17, 2016
Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal LymphomaBradley A Thuro, Jing Ning, S Andrew Peng, et al.
American Journal of Cancer Research|November 16, 2022
Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphomaFang Yu, Hua He, Loretta J Nastoupil, et al.
Haematologica|May 2, 2016
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesNathan H Fowler, Chan Yoon Cheah, Randy D Gascoyne, et al.
Eclinicalmedicine|August 20, 2024
Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trialAshwath Gurumurthi, Collin K Chin, Lei Feng, et al.
Pageof 6